Amplyx Ups Total Funding To $51.5M For Fungal Infection Treatment

San Diego-based Amplyx Pharmaceuticals, a developer of treatments for life threatening fungal infections, said it has added a new investor to its Series B funding, and has now raised a total of $51.5M for the company. 3x5 Partners joined investors in the company's $49.2M Series B. In addition to the funding, the company said it Michael Hodges, M.D., as chief medical officer; Karen Shaw, Ph.D., as vice president of biology; and Elizabeth Gordon, Ph.D., as vice president of regulatory affairs. Hodges was previously at Santaris Pharma A/S; Shaw was at Hearts Consulting Group; and Gordon was most recently at Shire Pharmaceuticals. More information »